Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb-Apr;23(1-2):25-35.
doi: 10.1016/j.cytogfr.2012.01.003. Epub 2012 Feb 16.

Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis

Affiliations
Review

Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis

Chen Huang et al. Cytokine Growth Factor Rev. 2012 Feb-Apr.

Abstract

Pancreatic cancer progression is attributed to genetic and epigenetic alterations and a chaotic tumor microenvironment. Those diverse "upstream signal" factors appear to converge on specific sets of central nuclear regulators, namely, transcription factors. Specificity Protein 1 (Sp1) and signal transducer and activator of transcription 3 (Stat3) are central transcription factors that regulate a number of pathways important to tumorigenesis, including tumor cell-cycle progression, apoptosis, angiogenesis, metastasis, and evasion of the immune system. Recently, researchers demonstrated many types of crosstalk of Sp1 and Stat3 in tumor signal transduction and that these factors function cooperatively to activate targeted genes and promote tumorigenesis in pancreatic cancer. Therefore, targeting both Sp1 and Stat3 is a potential preventive and therapeutic strategy for pancreatic cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Function of Sp1 in pancreatic cancer cells.
Fig. 2
Fig. 2
Function of Stat3 in pancreatic cancer cells.
Fig. 3
Fig. 3
Sp1 and Stat3 collaborations in gene regulation.

Similar articles

Cited by

References

    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57. - PubMed
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17. - PubMed
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72. - PubMed
    1. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 2003;14:675–92. - PubMed

Publication types

MeSH terms

Substances